Akero Therapeutics, Inc. (AKRO) Stock Analysis

Akero Therapeutics, Inc. (AKRO) Healthcare & Pipeline Overview

Akero Therapeutics, Inc. is a clinical-stage biotechnology company specializing in developing efruxifermin (EFX) for nonalcoholic steatohepatitis (NASH), positioning itself within the competitive landscape of cardio-metabolic disease treatments. The company focuses on restoring metabolic balance through innovative therapies, addressing a significant unmet medical need.

What Is the Investment Thesis for AKRO?

Akero Therapeutics presents a focused investment opportunity centered on its lead drug candidate, efruxifermin (EFX), targeting the multi-billion dollar NASH market. The ongoing Phase 2a BALANCED study results will be a key catalyst, potentially validating EFX's efficacy in biopsy-confirmed NASH patients. Positive clinical data could drive significant stock appreciation. However, the company faces risks associated with clinical trial outcomes, regulatory approvals, and competition from other pharmaceutical companies developing NASH treatments. With a market cap of $4.50B and a beta of -0.40, Akero demonstrates moderate market volatility. Success hinges on EFX's ability to demonstrate superior clinical benefits and secure regulatory approval, making it a high-risk, high-reward investment.

Based on FMP financials and quantitative analysis

AKRO Key Highlights

Akero Therapeutics is focused on developing efruxifermin (EFX) for the treatment of NASH, a disease with a significant unmet medical need.

• The company's lead product candidate, EFX, is currently in Phase 2a clinical trials, with potential for future advancement to later-stage trials.
• Akero Therapeutics changed its name from Pippin Pharmaceuticals, Inc. in May 2018, reflecting its strategic shift towards metabolic disease therapies.
• The company has a market capitalization of $4.50B, indicating substantial investor interest in its pipeline and potential.
• Akero Therapeutics operates with 69 employees, suggesting a lean and focused operational structure.

Who Are AKRO's Competitors?

AKRO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AKRO's Key Strengths?

Promising lead product candidate (EFX) targeting NASH.

• Strong scientific expertise in metabolic diseases.
• Ongoing Phase 2a clinical trial provides near-term data catalysts.
• Experienced management team.

What Are AKRO's Weaknesses?

Reliance on a single lead product candidate.

• Limited commercial infrastructure.
• High cash burn rate associated with clinical development.
• Subject to regulatory approval risks.

What Could Drive AKRO Stock Higher?

AKRO catalyst: Data readout from the Phase 2a BALANCED study evaluating EFX in NASH patients in Q4 2026.

• Potential initiation of Phase 3 clinical trials for EFX in 2027, pending Phase 2a results.
• Enrollment and progress in ongoing clinical trials for EFX.
• Potential for strategic partnerships and collaborations to support development and commercialization.

What Are the Key Risks for AKRO?

Negative return on equity (-30.7%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Unfavorable clinical trial results for EFX.
• Regulatory setbacks or delays in the approval process.
• Competition from other companies developing NASH treatments.
• High cash burn rate associated with clinical development.
• Reliance on a single lead product candidate.

What Are the Growth Opportunities for AKRO?

• Advancement of Eruxifermin (EFX) through Clinical Trials: Akero's primary growth opportunity lies in the successful advancement of EFX through clinical trials. Positive results from the ongoing Phase 2a BALANCED study could pave the way for Phase 3 trials and eventual regulatory approval. Timeline: Ongoing, with potential for Phase 3 initiation in 2027.
• Expansion of EFX into Related Metabolic Diseases: Beyond NASH, EFX has the potential to be developed for other metabolic diseases, such as type 2 diabetes and hyperlipidemia. These conditions share similar underlying metabolic dysfunctions, making EFX a potentially versatile therapeutic option. Expanding the target patient population could significantly increase Akero's market reach and revenue potential. Timeline: Exploratory research and preclinical studies could begin in 2027-2028.
• Strategic Partnerships and Collaborations: Akero could pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of EFX. Collaborations could provide access to additional funding, expertise, and resources, enhancing Akero's ability to navigate the complex regulatory landscape and reach a wider patient population. Timeline: Ongoing, with potential for partnership announcements in the next 1-2 years.
• Geographic Expansion into International Markets: While currently focused on the US market, Akero could expand its operations into international markets, such as Europe and Asia, where NASH prevalence is also increasing. Entering new markets would require regulatory approvals and commercial infrastructure, but could significantly increase Akero's long-term growth potential. Timeline: Potential expansion into Europe and Asia starting in 2029-2030.
• Development of Next-Generation NASH Therapies: Akero could leverage its expertise in metabolic diseases to develop next-generation NASH therapies that address different aspects of the disease or offer improved efficacy and safety compared to EFX. Investing in research and development of novel drug candidates could ensure Akero's long-term competitiveness in the NASH market. Timeline: Research and development of new therapies could commence in 2028-2029.

What Are AKRO's Competitive Advantages?

• Proprietary drug candidate (EFX) with a unique mechanism of action.
• Intellectual property protection for EFX and related technologies.
• Clinical data demonstrating the efficacy and safety of EFX.
• Expertise in the development of therapies for metabolic diseases.

What Does AKRO Do?

Akero Therapeutics, Inc., established in 2017 and headquartered in South San Francisco, California, is a cardio-metabolic NASH company dedicated to developing innovative medicines. Originally named Pippin Pharmaceuticals, Inc., the company rebranded in May 2018 to reflect its focus on developing therapies for metabolic diseases. Akero's primary focus is on nonalcoholic steatohepatitis (NASH), a severe liver disease characterized by inflammation and fat accumulation. Their lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21 (FGF21), designed to protect against cellular stress and regulate the metabolism of lipids, carbohydrates, and proteins throughout the body. EFX aims to restore metabolic balance and improve overall health in NASH patients. The company is currently conducting clinical trials, including a Phase 2a clinical trial called the BALANCED study, to evaluate the safety and efficacy of EFX in biopsy-confirmed NASH patients. Akero Therapeutics is committed to addressing the unmet medical needs of patients with NASH and other metabolic disorders through its innovative therapeutic approach.

What Products and Services Does AKRO Offer?

• Develop efruxifermin (EFX) as a treatment for nonalcoholic steatohepatitis (NASH).
• Conduct clinical trials to evaluate the safety and efficacy of EFX.
• Focus on restoring metabolic balance in patients with NASH and related metabolic disorders.
• Research and develop innovative medicines for cardio-metabolic diseases.
• Target the underlying metabolic dysfunctions associated with NASH.
• Seek regulatory approval for EFX from health authorities like the FDA.

How Does AKRO Make Money?

• Develop and commercialize pharmaceutical products for the treatment of NASH.
• Generate revenue through the sale of EFX upon regulatory approval.
• Fund research and development activities through venture capital and potential partnerships.
• Out-license or co-develop EFX with larger pharmaceutical companies for broader market access.

What Industry Does AKRO Operate In?

Akero Therapeutics operates within the biotechnology industry, specifically targeting the NASH market. The NASH market is expected to grow significantly due to the increasing prevalence of obesity and diabetes, major risk factors for NASH. The competitive landscape includes companies like Arcellx, Inc. (ACLX), Praxis Precision Medicines, Inc. (PRAX), Immunovant, Inc. (IMVT), Centessa Pharmaceuticals plc (CNTA), and Crinetics Pharmaceuticals, Inc. (CRNX), all vying for a share of the NASH treatment market. Akero's success depends on demonstrating superior efficacy and safety compared to existing and emerging therapies.

Who Are AKRO's Key Customers?

• Patients diagnosed with nonalcoholic steatohepatitis (NASH).
• Hospitals and clinics that treat patients with NASH.
• Physicians specializing in hepatology and gastroenterology.
• Healthcare providers involved in the management of metabolic diseases.

Akero Therapeutics, Inc. (AKRO) Valuation Context

Valued at $4.50B, AKRO is classified as a mid-cap stock. Analyst price targets span from $38.00 to $56.00, with a consensus of $48.40. At the current price of $54.65, that implies roughly 11% downside from the consensus target.

AKRO Revenue & Earnings Trend

In Q3 FY2025, AKRO generated $0 in top-line revenue. The company recorded a net loss of $81.6M, with diluted EPS of $-0.99. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, AKRO averaged $-0.94 in diluted EPS.

Company Profile

Akero Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Andrew Cheng. AKRO has traded publicly since 2019.

Return on equity for Akero Therapeutics, Inc. stands at -30.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -29.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -5.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 15.83 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.5%, the inverse of the P/E and a quick read on earnings relative to price.

Akero Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 54.74 places it in the safe zone, indicating low near-term bankruptcy risk.

Akero Therapeutics, Inc. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 20.8% above estimates on average.

Wall Street analysts project Akero Therapeutics, Inc. revenue of about $3.2M for fiscal 2026, with EPS near $-4.31. The estimate reflects 4 contributing analysts.

The most recent 12 insider filings for Akero Therapeutics, Inc. break down as 12 sales and 0 purchases. On net that is roughly 558K shares disposed (about $11.8M), a signal worth weighing alongside the fundamentals.

AKRO Financials

AKRO Latest News

Akero Therapeutics, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources